ArticleCureus2026
Topical Gentamicin in the Management of Bart Syndrome: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bart syndrome is a rare congenital disorder characterized by localized absence of skin, epidermolysis bullosa (EB), and nail abnormalities. We report the case of a female newborn presenting with congenital absence of skin on both feet, associated to multiple blisters in friction-prone areas and paronychia. Despite these findings, she remained clinically stable, was feeding normally, and exhibited no gastrointestinal symptoms. Based on the association of aplasia cutis and epidermolysis bullosa, a diagnosis of Bart syndrome was clinically suspected. The patient was treated with topical gentamicin 0.5% diluted in petroleum jelly, applied twice weekly, combined with a non-adhesive dressing. Clinical improvement was observed, with complete healing of the perineal lesions within three months and significant regression of limb involvement. Although spontaneous re-epithelialization is part of the natural course of the disease, the rapid and sustained clinical evolution raises the possibility of a beneficial effect of gentamicin. To the best of our knowledge, similar responses in this specific context have rarely been reported. Larger studies are required to confirm efficacy, define optimal treatment protocols, and evaluate long-term safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.